Lentigen
Gaithersburg · Founded 2005
About Lentigen
Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.
Company Facts
- Founded: 2005
- Legal name: Lentigen Corporation
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.2M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2012)
- Website: lentigen.com
- Phone: +13015274234
Canonical: https://fsome.com/organization/lentigen-8441189 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.